-
Germline GATA1 exon 2 mutation associated with chronic cytopenia and a non-down syndrome transient abnormal myelopoiesis with clonal trisomy 21 Leukemia (IF 12.883) Pub Date : 2022-08-08 Ricardo Camargo, Sushree S. Sahoo, José Carlos Córdoba, Isis Quezado Magalhães
-
A phase two study of high dose blinatumomab in Richter’s syndrome Leukemia (IF 12.883) Pub Date : 2022-08-08 Philip A. Thompson, Xianli Jiang, Pinaki Banerjee, Rafet Basar, Naveen Garg, Ken Chen, Mecit Kaplan, Vandana Nandivada, Ana Karen Nunez Cortes, Alessandra Ferrajoli, Michael J. Keating, Christine B. Peterson, Michael Andreeff, Katayoun Rezvani, William G. Wierda
-
Alternatively spliced CSF3R isoforms in SRSF2 P95H mutated myeloid neoplasms Leukemia (IF 12.883) Pub Date : 2022-08-08 Borwyn A. Wang, Hrishikesh M. Mehta, Srinivasa R. Penumutchu, Blanton S. Tolbert, Chonghui Cheng, Marek Kimmel, Torsten Haferlach, Jaroslaw P. Maciejewski, Seth J. Corey
-
In iron-deficient mouse pregnancies, erythroferrone contributes to iron mobilization for embryo erythropoiesis Am. J. Hematol. (IF 13.265) Pub Date : 2022-08-07 Veena Sangkhae, Vivian Yu, Richard Coffey, Kimberly O. O'Brien, Tomas Ganz, Elizabeta Nemeth
Erythroferrone (ERFE) is an erythroblast-secreted regulator of iron metabolism. The production of ERFE increases during stress erythropoiesis, leading to decreased hepcidin expression and mobilization of iron. Pregnancy requires a substantial increase in iron availability to sustain maternal erythropoietic expansion and fetal development and is commonly affected by iron deficiency. To define the role
-
The role of hypoxia and inflammation in the regulation of iron metabolism and erythropoiesis in COVID-19: the IRONCOVID Study Am. J. Hematol. (IF 13.265) Pub Date : 2022-08-05 D. Maira, L. Duca, F. Busti, D. Consonni, M. Salvatici, A. Vianello, A. Milani, A. Guzzardella, E. Di Pierro, S. Aliberti, I. M. Baldini, A. Bandera, F. Blasi, E. Cassinerio, M. Cesari, A. L. Fracanzani, G. Grasselli, G. Graziadei, R. Lombardi, G. Marchi, N. Montano, V. Monzani, F. Peyvandi, M. Proietti, M. Sandri, L. Valenti, M. D. Cappellini, D. Girelli, A. Protti, I. Motta
Coronavirus Disease (COVID-19) can be considered as a human pathological model of inflammation combined with hypoxia. In this setting, both erythropoiesis and iron metabolism appear to be profoundly affected by inflammatory and hypoxic stimuli, which act in the opposite direction on hepcidin regulation. The impact of low blood oxygen levels on erythropoiesis and iron metabolism in the context of human
-
A bioinformatics perspective on molecular classification of diffuse large B-cell lymphoma Leukemia (IF 12.883) Pub Date : 2022-08-06 Matias Mendeville, Jurriaan Janssen, Yongsoo Kim, Erik van Dijk, Daphne de Jong, Bauke Ylstra
-
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease Leukemia (IF 12.883) Pub Date : 2022-08-06 Jan Zuna, Lenka Hovorkova, Justina Krotka, Amelie Koehrmann, Michela Bardini, Lucie Winkowska, Eva Fronkova, Julia Alten, Rolf Koehler, Cornelia Eckert, Lisa Brizzolara, Marie Trkova, Jan Stuchly, Martin Zimmermann, Paola De Lorenzo, Maria Grazia Valsecchi, Valentino Conter, Jan Stary, Martin Schrappe, Andrea Biondi, Jan Trka, Marketa Zaliova, Giovanni Cazzaniga, Gunnar Cario
-
Anti-COX-2 autoantibody is a novel biomarker of immune aplastic anemia Leukemia (IF 12.883) Pub Date : 2022-08-05 Tiina Kelkka, Mikko Tyster, Sofie Lundgren, Xingmin Feng, Cassandra Kerr, Kohei Hosokawa, Jani Huuhtanen, Mikko Keränen, Bhavisha Patel, Toru Kawakami, Yuka Maeda, Otso Nieminen, Tiina Kasanen, Pasi Aronen, Bhagwan Yadav, Hanna Rajala, Hideyuki Nakazawa, Taina Jaatinen, Eva Hellström-Lindberg, Seishi Ogawa, Fumihiro Ishida, Hiroyoshi Nishikawa, Shinji Nakao, Jaroslaw Maciejewski, Neal S. Young, Satu
-
Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-08-03 Lee, Sangmin, Mohan, Sanjay, Knupp, Jessica, Chamoun, Kamal, de Jonge, Adrienne, Yang, Fan, Baloglu, Erkan, Shah, Jatin, Kauffman, Michael G., Shacham, Sharon, Bhatnagar, Bhavana
Patients with higher-risk myelodysplastic syndromes (MDS) refractory to hypomethylating agents (HMAs) have limited therapeutic options and an expected overall survival (OS) of 3–5 months. Eltanexor is an investigational oral selective inhibitor of nuclear export with low central nervous system penetrance and an acceptable tolerability profile. Preclinical studies suggest that myeloid malignancies are
-
Venetoclax ex vivo functional profiling predicts improved progression-free survival Blood Cancer J. (IF 9.812) Pub Date : 2022-08-04 Vikas A. Gupta, Shannon M. Matulis, Benjamin G. Barwick, R. Devin Bog, Conrad W. Shebelut, Mala Shanmugam, Paola Neri, Nizar J. Bahlis, Madhav V. Dhodapkar, Leonard T. Heffner, Craig C. Hofmeister, Nisha S. Joseph, Sagar Lonial, Jonathan L. Kaufman, David L. Jaye, Ajay K. Nooka, Lawrence H. Boise
-
Early expression of CD94 and loss of CD96 on CD8+ T cells after allogeneic SCT is predictive of subsequent relapse and survival. Haematologica (IF 11.047) Pub Date : 2022-08-04 Kriti Verma, Wayne Croft, Hayden Pearce, Jianmin Zuo, Christine Stephens, Jane Nunnick, Francesca Am Kinsella, Ram Malladi, Paul Moss
Allogeneic stem cell transplantation is used widely in the treatment of hematopoietic malignancy. However relapse of malignant disease is the primary cause of treatment failure and reflects loss of immunological graft versus leukaemia effect. We studied the transcriptional and phenotypic profile of CD8+ T cells in the first month following transplantation and related this to risk of subsequent relapse
-
Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission. Haematologica (IF 11.047) Pub Date : 2022-08-04 Stephanie Dulucq, Sandrine Hayette, Jean-Michel Cayuela, Frédéric Bauduer, Kaddour Chabane, Patrice Chevallier, Pascale Cony-Makhoul, Pascale Flandrin-Gresta, Caroline Le Jeune, Yannick Le Bris, Laurence Legros, Hervé Maisonneuve, Lydia Roy, Francois-Xavier Mahon, Ivan Sloma, Delphine Rea, Franck Emmanuel Nicolini
Not available.
-
ARID5B influences B cell development and function in mouse. Haematologica (IF 11.047) Pub Date : 2022-08-04 Charnise Goodings, Xujie Zhao, Shannon McKinney-Freeman, Hui Zhang, Jun J Yang
There is growing evidence for an inherited basis of susceptibility to childhood acute lymphoblastic leukemia (ALL). Genome-wide association studies by us and others have identified non-coding ALL risk variants at the ARID5B gene locus, but the molecular mechanisms linking ARID5B to normal and malignant hematopoiesis remain largely unknown. Using a Vav1-driven transgenic mouse model, we characterized
-
Morbidity and mortality of sickle cell disease patients is unaffected by splenectomy: evidence from 3 decades follow-up in a high-income setting. Haematologica (IF 11.047) Pub Date : 2022-08-04 Valeria Maria Pinto, Barbara Gianesin, Frédéric B Piel, Filomena Longo, Paolo Rigano, Alessandra Quota, Vincenzo Spadola, Giovanna Graziadei, Filippo Mazzi, Maria Domenica Cappellini, Aurelio Maggio, Antonio Piga, Lucia De Franceschi, Gian Luca Forni
Not available.
-
Mass-spectrometry-based proteomics amyloid typing in clinical practice: state-of-the-art from a French nationwide cohort. Haematologica (IF 11.047) Pub Date : 2022-08-04 Magali Colombat, Margot Gaspard, Mylène Camus, Jessica Dalloux-Chioccioli, Audrey Delas, Elsa Poullot, Anissa Moktefi, Arnaud François, Anne Moreau, Jean-Bapiste Gibier, Pierre Raynaud, Antoine Huart, Alexis Piedrafita, Julia Gilhodes, Olivier Lairez, Gilles Grateau, Sophie Georgin-Lavialle, Hervé Maisonneuve, Philippe Moreau, Arnaud Jaccard, Franck Bridoux, Violaine Plante-Bordeneuve, Thibaud Damy
Not available.
-
Clinical and biological impact of ATP-binding cassette transporter activity in adult acute myeloid leukemia. Haematologica (IF 11.047) Pub Date : 2022-08-04 Elise Sourdeau, Ludovic Suner, Mara Memoli, Alexis Genthon, Frédéric Feger, Lou Soret, Nasséra Abermil, Laurence Heuberger, Chrystele Bilhou-Nabera, Hélène Guermouche, Fabrizia Favale, Simona Lapusan, Michael Chaquin, Claire Hirschauer, Mohamad Mohty, Ollivier Legrand, François Delhommeau, Pierre Hirsch
Chemotherapy resistance is the main cause of treatment failure in acute myeloid leukemia (AML) and has been related to ATP-binding cassette (ABC) transporter activity. However, the links between ABC activity, immunophenotype, and molecular AML parameters have been poorly evaluated. Moreover, the prognostic value of ABC activity, when compared to new molecular markers, is unknown. Here we investigated
-
Translational readthrough at F8 nonsense variants in factor VIII B domain contributes to residual expression and lowers inhibitor association. Haematologica (IF 11.047) Pub Date : 2022-08-04 Maria Francesca Testa, Silvia Lombardi, Francesco Bernardi, Mattia Ferrarese, Donata Belvini, Paolo Radossi, Giancarlo Castaman, Mirko Pinotti, Alessio Branchini
In hemophilia A (HA), F8 nonsense variants, and particularly those affecting the large factor VIII (FVIII) B domain that is dispensable for coagulant activity, display lower association with replacement therapy-related anti-FVIII inhibitory antibodies as retrieved from multiple international databases. Since null genetic conditions favour inhibitor development, we hypothesized that translational readthrough
-
Splenectomy in sickle cell disease: do benefits outweigh risks? Haematologica (IF 11.047) Pub Date : 2022-08-04 Amina Nardo-Marino, Valentine Brousse
Not available.
-
Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia. Haematologica (IF 11.047) Pub Date : 2022-08-04 Corentin Orvain, Jacob A Wilson, Min Fang, Brenda M Sandmaier, Eduardo Rodríguez-Arbolí, Brent L Wood, Megan Othus, Frederick R Appelbaum, Roland B Walter
Measurable residual disease (MRD) before hematopoietic cell transplantation (HCT) is an independent established prognostic factor in patients with acute myeloid leukemia (AML). Several methods exist to evaluate the presence of residual leukemia cells, but how these are used best in combination is unclear. To examine how residual cytogenetic abnormalities and MRD testing by multiparameter flow cytometry
-
Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia. Haematologica (IF 11.047) Pub Date : 2022-08-04 Raffaele Palmieri, Megan Othus, Guang-Shing Cheng, Francesco Buccisano, Giovangiacinto Paterno, Luca Maurillo, Maria Ilaria Del Principe, Giuseppe Sconocchia, Adriano Venditti, Roland B Walter
Not available.
-
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial Leukemia (IF 12.883) Pub Date : 2022-08-03 Nikolaus Jahn, Ekaterina Jahn, Maral Saadati, Lars Bullinger, Richard A. Larson, Tiziana Ottone, Sergio Amadori, Thomas W. Prior, Joseph M. Brandwein, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Gerhard Ehninger, Michael Heuser, Arnold Ganser, Celine Pallaud, Insa Gathmann, Julia Krzykalla, Axel Benner, Clara D. Bloomfield, Christian Thiede, Richard M. Stone, Hartmut Döhner, Konstanze
-
Correction to Lancet Haematol 2022; Published online July 27. https://doi.org/10.1016/S2352-3026(22)00206-X Lancet Haematol. (IF 30.153) Pub Date : 2022-08-01
Abstract not available
-
High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance Leukemia (IF 12.883) Pub Date : 2022-08-01 Hui Yang, Guillermo Garcia-Manero, Koji Sasaki, Guillermo Montalban-Bravo, Zhenya Tang, Yue Wei, Tapan Kadia, Kelly Chien, Diana Rush, Ha Nguyen, Awdesh Kalia, Manjunath Nimmakayalu, Carlos Bueso-Ramos, Hagop Kantarjian, L. Jeffrey Medeiros, Rajyalakshmi Luthra, Rashmi Kanagal-Shamanna
-
Cancer Risk and Gammopathies in 2,123 Adults with Gaucher Disease Type 1 in the International Gaucher Group Gaucher Registry Am. J. Hematol. (IF 13.265) Pub Date : 2022-08-02 Barry E. Rosenbloom, Maria Domenica Cappellini, Neal J. Weinreb, Marta Dragosky, Shoshana Revel-Vilk, Julie L. Batista, Davorka Sekulic, Pramod K. Mistry
There are numerous reports of cancers in Gaucher disease from mostly small single-center studies; however, precise risk estimates and cancer types involved have not been delineated. We conducted a study involving 2123 patients with Gaucher disease type 1 (GD1) to assess the incidence of hematological malignancies, gammopathies, and solid tumors in an international observational study, the International
-
Inhibition of the m6A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemia Leukemia (IF 12.883) Pub Date : 2022-08-01 Panpan Feng, Dawei Chen, Xia Wang, Yanxia Li, Zhenyu Li, Boya Li, Yupeng Zhang, Wei Li, Jingru Zhang, Jingjing Ye, Baobing Zhao, Jingxin Li, Chunyan Ji
-
Tfr2 Genetic Deletion Makes Transfusion-Independent a Murine Model of Transfusion-Dependent β-Thalassemia Am. J. Hematol. (IF 13.265) Pub Date : 2022-08-01 Simona Maria Di Modica, Emanuele Tanzi, Violante Olivari, Maria Rosa Lidonnici, Mariateresa Pettinato, Alessia Pagani, Francesca Tiboni, Valeria Furiosi, Laura Silvestri, Giuliana Ferrari, Stefano Rivella, Antonella Nai
β-thalassemia is a genetic disorder caused by mutations in the β-globin gene, and characterized by anemia, ineffective erythropoiesis and iron overload. Patients affected by the most severe transfusion-dependent form of the disease (TDT) require lifelong blood transfusions and iron chelation therapy, a symptomatic treatment associated with several complications. Other therapeutic opportunities are
-
Correction: hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-07-31 Su, Yan, Sun, Xueyan, Liu, Xiao, Qu, Qingyuan, Yang, Liping, Chen, Qi, Liu, Fengqi, Li, Yueying, Wang, Qianfei, Huang, Bo, Zhang, Xiao-Hui, Huang, Xiao-Jun
The original article [1] contained errors in the names of co-authors, Xiao-Jun Huang and Xiao-Hui Zhang which have since been corrected. Su Y, Sun X, Liu X, et al. hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype. J Hematol Oncol. 2022;15:99. https://doi.org/10.1186/s13045-022-01315-2. Article PubMed PubMed Central Google Scholar Download referencesAuthor
-
Time-dependent prediction of mortality and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation using machine learning Am. J. Hematol. (IF 13.265) Pub Date : 2022-07-31 Lisa Eisenberg, , Christian Brossette, Jochen Rauch, Andrea Grandjean, Hellmut Ottinger, Jürgen Rissland, Ulf Schwarz, Norbert Graf, Dietrich W. Beelen, Stephan Kiefer, Nico Pfeifer, Amin T. Turki
Allogeneic hematopoietic cell transplantation (HCT) effectively treats high-risk hematologic diseases but can entail HCT-specific complications, which may be minimized by appropriate patient management, supported by accurate, individual risk estimation. However, almost all HCT risk scores are limited to a single risk assessment before HCT without incorporation of additional data. We developed machine
-
Requirement for TP73 and genetic alterations originating from its intragenic super-enhancer in adult T-cell leukemia Leukemia (IF 12.883) Pub Date : 2022-07-30 Jolynn Zu Lin Ong, Rui Yokomori, Regina Wan Ju Wong, Tze King Tan, Ryuzo Ueda, Takashi Ishida, Shinsuke Iida, Takaomi Sanda
-
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia Leukemia (IF 12.883) Pub Date : 2022-07-30 Simona Soverini, Sara De Santis, Margherita Martelli, Cecilia Monaldi, Fausto Castagnetti, Gabriele Gugliotta, Cristina Papayannidis, Manuela Mancini, Samantha Bruno, Claudia Venturi, Katerina Machova Polakova, Thomas Ernst, Dianna Maar, Adam Corner, Michele Cavo
-
SLIT2 promoter hypermethylation-mediated SLIT2-IT1/miR-218 repression drives leukemogenesis and predicts adverse prognosis in myelodysplastic neoplasm Leukemia (IF 12.883) Pub Date : 2022-07-29 Ting-juan Zhang, Zi-jun Xu, Xiang-mei Wen, Yu Gu, Ji-chun Ma, Qian Yuan, Jiang Lin, Jing-dong Zhou, Jun Qian
-
Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial Lancet Haematol. (IF 30.153) Pub Date : 2022-07-27 Amy E DeZern, Mary Eapen, Juan Wu, Julie-An Talano, Melhem Solh, Blachy J Dávila Saldaña, Chatchada Karanes, Mitchell E Horwitz, Kanwaldeep Mallhi, Sally Arai, Nosha Farhadfar, Elizabeth Hexner, Peter Westervelt, Joseph H Antin, H Joachim Deeg, Eric Leifer, Robert A Brodsky, Brent R Logan, Michael A Pulsipher
Background Relapsed severe aplastic anaemia is a marrow failure disorder with high morbidity and mortality. It is often treated with bone marrow transplantation at relapse post-immunosuppressive therapy, but under-represented minorities often cannot find a suitably matched donor. This study aimed to understand the 1-year overall survival in patients with relapsed or refractory severe aplastic anaemia
-
Haploidentical bone marrow transplantation for severe aplastic anaemia: looking to the future Lancet Haematol. (IF 30.153) Pub Date : 2022-07-27 Camilla Frieri, Luana Marano
Abstract not available
-
Clinical and immunophenotypic characteristics of familial leukemia predisposition caused by PAX5 germline variants Leukemia (IF 12.883) Pub Date : 2022-07-28 Adela Escudero, Masatoshi Takagi, Franziska Auer, Ulrike Anne Friedrich, Satoshi Miyamoto, Atsushi Ogawa, Kohsuke Imai, Barbara Pascual, María Vela, Polina Stepensky, Layal Yasin, Sarah Elitzur, Arndt Borkhardt, Antonio Pérez-Martínez, Julia Hauer
-
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia Leukemia (IF 12.883) Pub Date : 2022-07-28 Lioba Schönfeld, Jenny Rinke, Anna Hinze, Saskia N. Nagel, Vivien Schäfer, Thomas Schenk, Christian Fabisch, Tim H. Brümmendorf, Andreas Burchert, Philipp le Coutre, Stefan W. Krause, Susanne Saussele, Fatemeh Safizadeh, Markus Pfirrmann, Andreas Hochhaus, Thomas Ernst
-
Identification of proliferative and non-proliferative subpopulations of leukemic cells in CLL Leukemia (IF 12.883) Pub Date : 2022-07-28 Kirsty M. Cuthill, Yan Zhang, Andrea Pepper, Lies Boelen, Eve Coulter, Becca Asquith, Stephen Devereux, Derek C. Macallan
-
Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia Leukemia (IF 12.883) Pub Date : 2022-07-27 Emma M. Groarke, Bhavisha A. Patel, Ruba Shalhoub, Fernanda Gutierrez-Rodrigues, Parth Desai, Harshraj Leuva, Yoshitaka Zaimoku, Casey Paton, Nina Spitofsky, Jennifer Lotter, Olga Rios, Richard W. Childs, David J. Young, Alina Dulau-Florea, Cynthia E. Dunbar, Katherine R. Calvo, Colin O. Wu, Neal S. Young
-
NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-07-28 Bi, Xiaoman, Zhang, Qing, Chen, Lei, Liu, Dan, Li, Yueying, Zhao, Xiaoxi, Zhang, Ya, Zhang, Liping, Liu, Jingkun, Wu, Chaoyi, Li, Zhigang, Zhao, Yunze, Ma, Honghao, Huang, Gang, Liu, Xin, Wang, Qian-fei, Zhang, Rui
Hemophagocytic lymphohistiocytosis (HLH), particularly primary HLH (pHLH), is a rare, life-threatening disease. Germline genetic deficiency of 12 known HLH genes impairs cytotoxic degranulation in natural killer (NK) cells or cytotoxic T lymphocytes (CTLs) and contributes to pHLH development. However, no pathogenic mutations in these HLH genes are found in nearly 10% of HLH patients, despite a strong
-
Improving the anti-acute myeloid leukemia activity of CD123-specific Engager T cells by MyD88 and CD40 costimulation. Haematologica (IF 11.047) Pub Date : 2022-07-28 Abishek Vaidya, Erin Doherty, Xiya Wu, Sujuan Huang, Nikhil Hebbar, Unmesha Thanekar, Challice L Bonifant, Cheng Cheng, Stephen Gottschalk, M Paulina Velasquez
The outcome of acute myeloid leukemia (AML) remains poor, and immunotherapy has the potential to improve this. T cells expressing chimeric antigen receptors (CARs) or bispecific T cell engagers targeting CD123 are actively being explored in preclinical and/or early phase clinical studies. We have shown that T cells expressing CD123-specific bispecific T cell engagers (CD123.ENG T cells) have anti-AML
-
Analysis of rare driving events in pediatric acute myeloid leukemia. Haematologica (IF 11.047) Pub Date : 2022-07-28 Sanne Noort, Jolieke van Oosterwijk, Jing Ma, Elizabeth A R Garfinkle, Stephanie Nance, Michael Walsh, Guangchun Song, Dirk Reinhardt, Martina Pigazzi, Franco Locatelli, Henrik Hasle, Jonas Abrahamsson, Marie Jarosova, Charikleia Kelaidi, Sophia Polychronopoulou, Marry M Van den Heuvel-Eibrink, Maarten Fornerod, Tanja A Gruber, C Michel Zwaan
Elucidating genetic aberrations in pediatric acute myeloid leukemia (AML) provides insight in biology and may impact on risk-group stratification and clinical outcome. This study aimed to detect such aberrations in a selected series of samples without known (cyto)genetic aberration using molecular profiling. A cohort of 161 patients was selected from various study groups: DCOG, BFM, SJCRH, NOPHO and
-
PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here? Haematologica (IF 11.047) Pub Date : 2022-07-28 Sigrid S Skanland, Jennifer R Brown
Phosphatidylinositol 3-kinase (PI3K) inhibitors are effective in chronic lymphocytic leukemia (CLL). However, the severe toxicity profile associated with the first-generation inhibitors idelalisib and duvelisib, combined with the availability of other more tolerable agents, have limited their use. CLL is still considered incurable, and relapse after treatment, development of resistance, and treatment
-
Getting (T-cells) ENGaged. Haematologica (IF 11.047) Pub Date : 2022-07-28 Susanne H C Baumeister
Not available.
-
Minnesota acute GvHD risk score predicts survival at onset of GvHD after PTCy prophylaxis. Haematologica (IF 11.047) Pub Date : 2022-07-28 Federica Ardizzoia, Francesca Lorentino, Alessandro Bruno, Sarah Marktel, Fabio Giglio, Daniela Clerici, Francesca Farina, Sara Mastaglio, Simona Piemontese, Andrea A Assanelli, Matteo G Carrabba, Massimo Bernardi, Consuelo Corti, Jacopo Peccatori, Fabio Ciceri, Raffaella Greco, Maria Teresa Lupo-Stanghellini
Not available.
-
Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis. Haematologica (IF 11.047) Pub Date : 2022-07-28 Lorenza Falini, Alessandra Venanzi, Valentina Tini, Alessandra Innocente, Stelvio Ballanti, Simonetta Saldi, Silvio Sivolella, Antonio Pierini, Cynthia Aristei, Enrico Tiacci, Vincenzo Maria Perriello, Brunangelo Falini
Not available.
-
Racial differences as predictors of outcomes in young patients with multiple myeloma Blood Cancer J. (IF 9.812) Pub Date : 2022-07-27 Alicia Bao, Qiuhong Zhao, Elizabeth Merritt, Naresh Bumma, Srinivas Devarakonda, Abdullah M. Khan, Elvira Umyarova, Ashley E. Rosko, Don M. Benson, Francesca Cottini
-
Cecilia Guillermo—leading Uruguay's battle against haematological diseases Lancet Haematol. (IF 30.153) Pub Date : 2022-07-25 Tony Kirby
Abstract not available
-
Correction: Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-07-26 Zhang, Yang, Chen, Xiaoyi, Wang, Huamin, Gordon-Mitchell, Shanisha, Sahu, Srabani, Bhagat, Tushar D., Choudhary, Gaurav, Aluri, Srinivas, Pradhan, Kith, Sahu, Plabani, Carbajal, Milagros, Zhang, Hui, Agarwal, Beamon, Shastri, Aditi, Martell, Robert, Starczynowski, Daniel, Steidl, Ulrich, Maitra, Anirban, Verma, Amit
The original article erroneously omitted the following Conflict of Interest statement: Dr. Maitra receives royalties from Cosmos Wisdom Biotech for a license related to a pancreatic cancer early detection test. He is also listed as an inventor on a patent licensed to Thrive Earlier Detection Ltd (an Exact Sciences Company) and serves as a consultant for Freenome and Tezcat Biotechnology. Authors and
-
Predicting the outcome for patients with myelofibrosis undergoing an allogeneic hemopoietic stem cell transplant Blood Cancer J. (IF 9.812) Pub Date : 2022-07-26 Federica Sora, Sabrina Giammarco, Anna Maria Raiola, Carmen Di Grazia, Stefania Bregante, Francesca Gualandi, Riccardo Varaldo, Patrizia Chiusolo, Simona Sica, Luca Laurenti, Idanna Innocenti, Francesco Autore, Elisabetta Metafuni, Eugenio Galli, Andrea Bacigalupo, Emanuele Angelucci
-
Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms Blood Cancer J. (IF 9.812) Pub Date : 2022-07-26 Marie-France Gagnon, Shulan Tian, Susan Geyer, Neeraj Sharma, Celine M. Vachon, Yael Kusne, P. Leif Bergsagel, A. Keith Stewart, S. Vincent Rajkumar, Shaji Kumar, Sikander Ailawadhi, Linda B. Baughn
-
Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma Blood Cancer J. (IF 9.812) Pub Date : 2022-07-26 Hassan B. Alkhateeb, Razan Mohty, Patricia Greipp, Radhika Bansal, Matthew Hathcock, Allison Rosenthal, Hemant Murthy, Mohamed Kharfan-Dabaja, Jose C. Bisneto Villasboas, Nora Bennani, Stephen M. Ansell, Mrinal M. Patnaik, Mark R. Litzow, Rong He, Dong Chen, Aref Al-Kali, Saad S. Kenderian, Yi Lin, Mithun Vinod Shah
-
International Society on Thrombosis and Haemostasis Congress 2022 Lancet Haematol. (IF 30.153) Pub Date : 2022-07-25 Lan-Lan Smith
Abstract not available
-
Thrombosis and mental health Lancet Haematol. (IF 30.153) Pub Date : 2022-07-25 The Lancet Haematology
Abstract not available
-
Choosing the ideal immunotherapy for high-risk ALL Lancet Haematol. (IF 30.153) Pub Date : 2022-07-25
Abstract not available
-
Empowering children and adolescents with sickle cell disease: a transition journey to adult care Lancet Haematol. (IF 30.153) Pub Date : 2022-07-25 Sherif M Badawy
Abstract not available
-
Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issues Lancet Haematol. (IF 30.153) Pub Date : 2022-07-25 Nina Worel, Mahmoud Aljurf, Chloe Anthias, Andreas S Buser, Meghann Cody, Mirjam Fechter, Sebastian Galeano, Hildegard T Greinix, Annika M Kisch, Mickey B C Koh, Thilo Mengling, Grazia Nicoloso, Dietger Niederwieser, Michael A Pulsipher, Adriana Seber, Bronwen E Shaw, Heather E Stefanski, Galen E Switzer, Jörg P Halter
The contribution of related donors to the globally rising number of allogeneic haematopoietic stem cell transplantations (HSCT) remains increasingly important, particularly because of the growing use of haploidentical HSCT. Compared with the strict recommendations on the suitability for unrelated donors, criteria for related donors allow for more discretion and vary between centres. In 2015, the donor
-
Packed red blood cell transfusion in preterm infants Lancet Haematol. (IF 30.153) Pub Date : 2022-07-25 Luise Bellach, Michael Eigenschink, Abtin Hassanein, Danylo Savran, Ulrich Salzer, Ernst W Müllner, Andreas Repa, Katrin Klebermass-Schrehof, Lukas Wisgrill, Vito Giordano, Angelika Berger
Premature infants commonly receive adult packed red blood cells (pRBCs) during their hospital stay. As adult erythrocytes differ substantially from those of preterm infants, transfusion of adult pRBCs into preterm infants can be considered inappropriate for the physiology of a preterm infant. An absence of standardisation of transfusion protocols makes it difficult to compare and interpret pertinent
-
Immune senescence in multiple myeloma—a role for mitochondrial dysfunction? Leukemia (IF 12.883) Pub Date : 2022-07-25 Frances Seymour, Jonathan Carmichael, Claire Taylor, Christopher Parrish, Gordon Cook
-
Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia: Past Discoveries and Future Directions Am. J. Hematol. (IF 13.265) Pub Date : 2022-07-24 Nicholas J. Short, Hagop Kantarjian
Azacitidine and decitabine are hypomethylating agents that have dose-dependent epigenetic and cytotoxic effects and are widely used in the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In this review, we discuss the path to regulatory approval of azacitidine and decitabine, highlighting the substantial efforts that have been made to optimize the dosing schedule and
-
Characteristics and outcome of adults with severe autoimmune hemolytic anemia admitted to the intensive care unit: Results from a large French observational study Am. J. Hematol. (IF 13.265) Pub Date : 2022-07-24 Clara Pouchelon, Charlotte Lafont, Antoine Lafarge, Thibault Comont, Etienne Riviere, David Boutboul, Claire Fieschi, Antoine Dossier, Sylvain Audia, Julien Vaidie, Marc Ruivard, Delphine Gobert, Guillaume Bonnard, Julie Graveleau, Matthieu Mahevas, Bertrand Godeau, Marc Michel
Adult'autoimmune hemolytic anemia (AIHA), which is often seen as a rare and “benign” autoimmune hematological disease, can be life-threatening with an overall mortality rate from 8% to 20% depending on the series1-3 and a short-term mortality rate that can be up to 30% in intensive care units (ICUs).4 Factors associated with the need for ICU management of patients with severe AIHA remain partially
-
SARS-CoV-2 humoral responses following booster BNT162b2 vaccination in patients with B-cell malignancies Am. J. Hematol. (IF 13.265) Pub Date : 2022-07-24 Evangelos Terpos, Despina Fotiou, Vangelis Karalis, Ioannis Ntanasis-Stathopoulos, Aimilia D. Sklirou, Maria Gavriatopoulou, Panagiotis Malandrakis, Vassiliki A. Iconomidou, Efstathios Kastritis, Ioannis P. Trougakos, Meletios A. Dimopoulos